Seattle Genetics Stock Price, News & Analysis (NASDAQ:SGEN)

$54.61 -0.65 (-1.18 %)
(As of 12/13/2017 01:49 PM ET)
Previous Close$55.26
Today's Range$53.83 - $55.27
52-Week Range$45.31 - $71.32
Volume1.50 million shs
Average Volume973,023 shs
Market Capitalization$7.95 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.37

About Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics logoSeattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

Receive SGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGEN
CUSIP81257810
Phone425-527-4000

Debt

Debt-to-Equity RatioN/A
Current Ratio4.06%
Quick Ratio3.66%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$418.15 million
Price / Sales18.80
Cash FlowN/A
Price / CashN/A
Book Value$4.48 per share
Price / Book12.19

Profitability

Trailing EPS($0.86)
Net Income$-140,110,000.00
Net Margins-26.53%
Return on Equity-32.41%
Return on Assets-24.77%

Miscellaneous

Employees890
Outstanding Shares143,930,000

Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions

What is Seattle Genetics' stock symbol?

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

How were Seattle Genetics' earnings last quarter?

Seattle Genetics, Inc. (NASDAQ:SGEN) posted its earnings results on Thursday, October, 26th. The biotechnology company reported ($0.19) EPS for the quarter, beating the Zacks' consensus estimate of ($0.42) by $0.23. The biotechnology company had revenue of $135.29 million for the quarter, compared to analysts' expectations of $112.76 million. Seattle Genetics had a negative net margin of 26.53% and a negative return on equity of 32.41%. Seattle Genetics's revenue for the quarter was up 27.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.23) earnings per share. View Seattle Genetics' Earnings History.

When will Seattle Genetics make its next earnings announcement?

Seattle Genetics is scheduled to release their next quarterly earnings announcement on Wednesday, February, 7th 2018. View Earnings Estimates for Seattle Genetics.

Where is Seattle Genetics' stock going? Where will Seattle Genetics' stock price be in 2017?

21 Wall Street analysts have issued 12 month price targets for Seattle Genetics' shares. Their forecasts range from $48.00 to $75.00. On average, they anticipate Seattle Genetics' share price to reach $63.20 in the next year. View Analyst Ratings for Seattle Genetics.

What are Wall Street analysts saying about Seattle Genetics stock?

Here are some recent quotes from research analysts about Seattle Genetics stock:

  • 1. Cann analysts commented, "Seattle Genetics and Astellas Pharma announced today dosing of the first patient in EV-103 study in combination with two different checkpoint inhibitors, for first- or second-line treatment of patients with locally advanced or metastatic urothelial cancer. We have not included any sales or earnings from enfortumab vedotin by 2021 due to its stage of development, but we are encouraged by this development program. Our financial outlook for Seattle Genetics’ revenue remains unchanged for 2017-21." (11/8/2017)
  • 2. According to Zacks Investment Research, "Seattle Genetics beat both earnings and sales estimates in the third quarter of 2017. Concurrently, the company raised 2017 revenues outlook.The company has upped its guidance for 2017 driven by a robust performance of Adcetris in the first half. We are also encouraged by the company’s efforts to expand the drug’s label. The company’s collaboration with Takeda for the global development and commercialization of Adcetris is encouraging. However, dependence on one product – Adcetris– for growth has its inherent risks. The recent label expansion of Merck’s Keytruda in the lymphoma indication is likely to increase competition. Though the company has multiple candidates in its pipeline, most of them are in early stages of development. The company’s shares have outperformed the industry year to date." (11/6/2017)
  • 3. Cantor Fitzgerald analysts commented, "The Phase III ECHELON-1 study in previously untreated patients with advanced classical Hodgkin lymphoma met its primary endpoint of modified PFS (82.1% versus 77.2% at two years)." (6/26/2017)
  • 4. Cowen Inc analysts commented, "SGEN announced this morning that following an interim safety look of 33A’s pivotal." (6/19/2017)

Who are some of Seattle Genetics' key competitors?

Who are Seattle Genetics' key executives?

Seattle Genetics' management team includes the folowing people:

  • Clay B. Siegall Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 56)
  • Todd E. Simpson, Chief Financial Officer (Age 56)
  • Eric L. Dobmeier, Chief Operating Officer (Age 48)
  • Jean I. Liu J.D., Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary (Age 48)
  • Darren S. Cline, Executive Vice President - Commercial (Age 52)
  • Jonathan G. Drachman M.D., Chief Medical Officer, Executive Vice President - Research and Development (Age 55)
  • Vaughn B. Himes Ph.D., Chief Technical Officer (Age 56)
  • Felix J. Baker Ph.D., Lead Independent Director (Age 47)
  • Srinivas Akkaraju M.D. Ph.D., Independent Director (Age 49)
  • David W. Gryska, Independent Director (Age 61)

Who owns Seattle Genetics stock?

Seattle Genetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (10.78%), Capital International Investors (3.10%), Manning & Napier Advisors LLC (1.80%), Pictet Asset Management Ltd. (0.89%), Capital Guardian Trust Co. (0.74%) and Wasatch Advisors Inc. (0.71%). Company insiders that own Seattle Genetics stock include Clay B Siegall, Darren S Cline, Eric Dobmeier, Felix Baker, John A Orwin, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.

Who sold Seattle Genetics stock? Who is selling Seattle Genetics stock?

Seattle Genetics' stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Baillie Gifford & Co., First Trust Advisors LP, Wells Fargo & Company MN, Candriam Luxembourg S.C.A., Lagoda Investment Management L.P., Wasatch Advisors Inc. and Canada Pension Plan Investment Board. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.

Who bought Seattle Genetics stock? Who is buying Seattle Genetics stock?

Seattle Genetics' stock was purchased by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, Capital International Investors, Pictet Asset Management Ltd., Capital Guardian Trust Co., Capital Bank & Trust Co, Capital International Ltd. CA, Asset Management One Co. Ltd. and Capital International Inc. CA. Company insiders that have bought Seattle Genetics stock in the last two years include Felix Baker and John A Orwin. View Insider Buying and Selling for Seattle Genetics.

How do I buy Seattle Genetics stock?

Shares of Seattle Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Seattle Genetics' stock price today?

One share of Seattle Genetics stock can currently be purchased for approximately $54.61.

How big of a company is Seattle Genetics?

Seattle Genetics has a market capitalization of $7.95 billion and generates $418.15 million in revenue each year. The biotechnology company earns $-140,110,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Seattle Genetics employs 890 workers across the globe.

How can I contact Seattle Genetics?

Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]


MarketBeat Community Rating for Seattle Genetics (SGEN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  328 (Vote Outperform)
Underperform Votes:  390 (Vote Underperform)
Total Votes:  718
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Seattle Genetics (NASDAQ:SGEN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.382.382.202.06
Ratings Breakdown: 1 Sell Rating(s)
11 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
11 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
10 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
11 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $63.20$62.93$58.57$59.77
Price Target Upside: 16.69% upside8.58% upside10.20% upside6.52% downside

Seattle Genetics (NASDAQ:SGEN) Consensus Price Target History

Price Target History for Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics (NASDAQ:SGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2017CowenReiterated RatingHold$54.00LowView Rating Details
12/12/2017Cantor FitzgeraldSet Price TargetHold$50.00MediumView Rating Details
12/7/2017OppenheimerReiterated RatingHoldMediumView Rating Details
11/13/2017Royal Bank of CanadaBoost Price TargetOutperform -> Outperform$68.00 -> $69.00N/AView Rating Details
11/8/2017CannInitiated CoverageHoldN/AView Rating Details
10/31/2017Morgan StanleyBoost Price TargetOverweight$64.00 -> $69.00N/AView Rating Details
10/30/2017J P Morgan Chase & CoBoost Price TargetNeutral$55.00 -> $60.00N/AView Rating Details
10/27/2017SunTrust BanksSet Price TargetHold$52.00N/AView Rating Details
10/27/2017HC WainwrightReiterated RatingBuy$75.00N/AView Rating Details
10/27/2017Bank of AmericaUpgradeUnderperform -> NeutralN/AView Rating Details
10/26/2017Jefferies GroupReiterated RatingBuy$53.00N/AView Rating Details
10/23/2017GuggenheimReiterated RatingBuy -> Buy$72.00N/AView Rating Details
10/20/2017BarclaysUpgradeEqual Weight -> Overweight$60.00 -> $70.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingNeutral -> Neutral$64.00N/AView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
6/27/2017Piper Jaffray CompaniesReiterated RatingNeutral$48.00HighView Rating Details
6/20/2017Needham & Company LLCReiterated RatingBuy$72.00LowView Rating Details
4/7/2017Leerink SwannBoost Price TargetOutperform$70.00 -> $74.00MediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
2/13/2017Credit Suisse GroupBoost Price TargetNeutral$62.00 -> $66.00N/AView Rating Details
1/5/2017Maxim GroupReiterated RatingReduceN/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Seattle Genetics (NASDAQ:SGEN) Earnings History and Estimates Chart

Earnings by Quarter for Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics (NASDAQ SGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2018($0.44)N/AView Earnings Details
10/26/2017Q3 2017($0.42)($0.19)$112.76 million$135.29 millionViewN/AView Earnings Details
7/27/2017Q2 2017($0.42)($0.39)$105.92 million$108.20 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.41)($0.42)$103.23 million$109.10 millionViewN/AView Earnings Details
2/9/2017Q416($0.34)($0.39)$106.49 million$105.30 millionViewListenView Earnings Details
10/27/2016Q316($0.29)($0.23)$4.34 million$106.30 millionViewListenView Earnings Details
7/26/2016Q216($0.32)($0.23)$94.56 million$95.40 millionViewListenView Earnings Details
4/28/2016Q116($0.09)($0.15)$116.49 million$111.15 millionViewListenView Earnings Details
2/9/2016Q415($0.20)($0.18)$88.00 million$93.50 millionViewN/AView Earnings Details
10/29/2015Q315($0.20)($0.21)$82.35 million$84.10 millionViewListenView Earnings Details
7/30/2015Q215($0.26)($0.38)$78.21 million$77.10 millionViewListenView Earnings Details
4/30/2015Q1($0.19)($0.17)$74.57 million$82.20 millionViewListenView Earnings Details
2/10/2015Q414($0.25)($0.22)$68.34 million$74.30 millionViewListenView Earnings Details
10/30/2014Q314($0.24)($0.13)$66.90 million$75.80 millionViewListenView Earnings Details
7/31/2014Q214($0.23)($0.14)$65.04 million$68.30 millionViewListenView Earnings Details
5/1/2014Q114($0.21)($0.13)$64.62 million$68.30 millionViewListenView Earnings Details
2/11/2014Q413($0.24)($0.13)$59.50 million$67.40 millionViewListenView Earnings Details
11/5/2013Q313($0.22)($0.19)$57.79 million$71.00 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.20)($0.06)$58.12 million$773.60 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.19)($0.14)$53.72 million$57.32 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.10)($0.09)$57.21 million$63.90 millionViewListenView Earnings Details
11/7/2012Q312($0.14)($0.12)$52.79 million$49.83 millionViewN/AView Earnings Details
8/8/2012($0.15)($0.15)ViewN/AView Earnings Details
5/8/2012($0.11)($0.11)ViewN/AView Earnings Details
2/13/2012($0.31)($0.24)ViewN/AView Earnings Details
11/3/2011($0.46)($0.35)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Seattle Genetics (NASDAQ:SGEN) Earnings Estimates

2017 EPS Consensus Estimate: ($1.51)
2018 EPS Consensus Estimate: ($1.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.39)($0.39)($0.39)
Q2 20173($0.44)($0.28)($0.37)
Q3 20174($0.47)($0.19)($0.34)
Q4 20174($0.50)($0.23)($0.41)
Q1 20181($0.42)($0.42)($0.42)
Q2 20181($0.33)($0.33)($0.33)
Q3 20181($0.25)($0.25)($0.25)
Q4 20181($0.38)($0.38)($0.38)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Seattle Genetics (NASDAQ:SGEN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Seattle Genetics (NASDAQ SGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 34.70%
Institutional Ownership Percentage: 98.94%
Insider Trades by Quarter for Seattle Genetics (NASDAQ:SGEN)
Institutional Ownership by Quarter for Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics (NASDAQ SGEN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/4/2017Eric DobmeierCOOSell3,729$58.75$219,078.75View SEC Filing  
11/30/2017Vaughn B. HimesInsiderSell10,000$59.97$599,700.00View SEC Filing  
11/17/2017Eric DobmeierCOOSell35,000$58.25$2,038,750.00View SEC Filing  
11/15/2017Eric DobmeierCOOSell9,600$57.80$554,880.00View SEC Filing  
11/15/2017Marc E. LippmanDirectorSell3,000$58.07$174,210.00View SEC Filing  
11/10/2017Clay B. SiegallInsiderSell18,832$58.00$1,092,256.00View SEC Filing  
11/1/2017Todd E. SimpsonCFOSell39,385$60.91$2,398,940.35View SEC Filing  
10/11/2017Clay B SiegallInsiderSell18,832$61.18$1,152,141.76View SEC Filing  
9/11/2017Clay B. SiegallInsiderSell18,832$53.49$1,007,323.68View SEC Filing  
9/8/2017Vaughn B. HimesInsiderSell10,000$53.22$532,200.00View SEC Filing  
9/6/2017Darren S. ClineEVPSell5,024$51.94$260,946.56View SEC Filing  
9/6/2017Todd E. SimpsonCFOSell9,638$52.00$501,176.00View SEC Filing  
8/31/2017Darren S. ClineEVPSell7,569$52.51$397,448.19View SEC Filing  
8/31/2017Eric DobmeierCOOSell25,000$52.24$1,306,000.00View SEC Filing  
8/28/2017Clay B. SiegallCEOSell25,506$47.89$1,221,482.34View SEC Filing  
8/28/2017Darren S. ClineEVPSell1,788$47.89$85,627.32View SEC Filing  
8/28/2017Eric DobmeierCOOSell5,343$47.89$255,876.27View SEC Filing  
8/28/2017Jonathan G. DrachmanCMOSell8,502$47.89$407,160.78View SEC Filing  
8/28/2017Todd E. SimpsonCFOSell4,937$47.89$236,432.93View SEC Filing  
8/28/2017Vaughn B. HimesInsiderSell6,377$47.89$305,394.53View SEC Filing  
8/24/2017Jonathan G. DrachmanCMOSell10,000$47.54$475,400.00View SEC Filing  
8/7/2017Clay B. SiegallInsiderSell10,413$48.91$509,299.83View SEC Filing  
8/7/2017Darren S. ClineEVPSell6,000$49.19$295,140.00View SEC Filing  
7/27/2017Jonathan G. DrachmanCMOSell10,000$54.54$545,400.00View SEC Filing  
7/5/2017Clay B. SiegallCEOSell10,423$51.98$541,787.54View SEC Filing  
6/22/2017Jonathan G DrachmanCMOSell10,000$64.01$640,100.00View SEC Filing  
6/5/2017Clay B. SiegallInsiderSell10,423$65.21$679,683.83View SEC Filing  
4/5/2017Clay B SiegallInsiderSell14,465$62.99$911,150.35View SEC Filing  
3/31/2017Vaughn B HimesInsiderSell10,000$62.75$627,500.00View SEC Filing  
3/6/2017Clay B SiegallCEOSell14,465$68.04$984,198.60View SEC Filing  
2/6/2017Clay B SiegallInsiderSell14,465$61.54$890,176.10View SEC Filing  
1/6/2017Clay B. SiegallInsiderSell14,465$57.89$837,378.85View SEC Filing  
12/13/2016Darren S. ClineEVPSell10,000$63.38$633,800.00View SEC Filing  
12/8/2016Eric DobmeierCOOSell12,500$65.92$824,000.00View SEC Filing  
12/7/2016Vaughn B. HimesInsiderSell30,000$65.32$1,959,600.00View SEC Filing  
11/8/2016Felix BakerDirectorBuy382,500$59.36$22,705,200.00View SEC Filing  
11/7/2016Clay B. SiegallCEOSell14,465$58.43$845,189.95View SEC Filing  
11/7/2016Marc E. LippmanDirectorSell1,000$57.75$57,750.00View SEC Filing  
11/3/2016Felix BakerDirectorBuy1,030,629$56.13$57,849,205.77View SEC Filing  
11/1/2016Jonathan G. DrachmanCMOSell3,418$51.74$176,847.32View SEC Filing  
10/6/2016Clay B. SiegallInsiderSell14,465$54.41$787,040.65View SEC Filing  
9/22/2016Jonathan G DrachmanCMOSell2,249$56.75$127,630.75View SEC Filing  
9/14/2016Eric DobmeierCOOSell22,918$54.04$1,238,488.72View SEC Filing  
9/13/2016Felix BakerDirectorBuy447,311$50.71$22,683,140.81View SEC Filing  
9/8/2016Clay B. SiegallInsiderSell31,269$50.08$1,565,951.52View SEC Filing  
9/8/2016Felix BakerDirectorBuy414,016$48.43$20,050,794.88View SEC Filing  
8/23/2016Eric DobmeierCOOSell12,589$48.00$604,272.00View SEC Filing  
8/22/2016Clay B. SiegallInsiderSell23,381$46.59$1,089,320.79View SEC Filing  
8/22/2016Eric DobmeierCOOSell5,411$46.59$252,098.49View SEC Filing  
8/22/2016Vaughn B. HimesEVPSell3,991$46.59$185,940.69View SEC Filing  
8/8/2016Clay B. SiegallInsiderSell11,660$47.19$550,235.40View SEC Filing  
7/27/2016Clay B. SiegallInsiderSell4,042$45.20$182,698.40View SEC Filing  
7/6/2016Clay B. SiegallCEOSell7,618$40.56$308,986.08View SEC Filing  
6/6/2016Clay B SiegallCEOSell22,083$43.59$962,597.97View SEC Filing  
6/2/2016Darren S ClineEVPSell3,366$42.07$141,607.62View SEC Filing  
5/27/2016Clay B SiegallCEOSell48,660$40.41$1,966,350.60View SEC Filing  
5/24/2016Clay B SiegallCEOSell8,400$40.09$336,756.00View SEC Filing  
5/23/2016Clay B SiegallCEOSell6,700$40.12$268,804.00View SEC Filing  
5/17/2016Clay B SiegallCEOSell7,618$35.16$267,848.88View SEC Filing  
4/25/2016Clay B SiegallCEOSell800$40.00$32,000.00View SEC Filing  
4/5/2016Clay B SiegallCEOSell7,618$36.12$275,162.16View SEC Filing  
3/22/2016Clay B SiegallCEOSell15,236$35.52$541,182.72View SEC Filing  
3/21/2016Clay B SiegallCEOSell4,282$35.01$149,912.82View SEC Filing  
3/17/2016Felix BakerDirectorBuy124,065$31.85$3,951,470.25View SEC Filing  
3/16/2016Felix BakerDirectorBuy1,349,237$32.10$43,310,507.70View SEC Filing  
3/15/2016Felix BakerDirectorBuy661,093$32.08$21,207,863.44View SEC Filing  
3/14/2016Felix BakerDirectorBuy118,941$33.77$4,016,637.57View SEC Filing  
3/11/2016Felix BakerDirectorBuy694,666$32.46$22,548,858.36View SEC Filing  
3/8/2016Felix BakerDirectorBuy502,523$22.66$11,387,171.18View SEC Filing  
3/2/2016Felix BakerDirectorBuy675,922$31.77$21,474,041.94View SEC Filing  
3/1/2016Felix BakerDirectorBuy24,200$31.24$756,008.00View SEC Filing  
2/29/2016Felix BakerDirectorBuy251,722$30.39$7,649,831.58View SEC Filing  
2/26/2016Felix BakerDirectorBuy314,508$29.55$9,293,711.40View SEC Filing  
2/22/2016Felix BakerDirectorBuy1,001,471$29.63$29,673,585.73View SEC Filing  
2/17/2016Felix BakerDirectorBuy1,269,147$30.43$38,620,143.21View SEC Filing  
2/12/2016John A. OrwinDirectorBuy2,000$28.33$56,660.00View SEC Filing  
12/15/2015Vaughn B. HimesEVPSell40,500$39.94$1,617,570.00View SEC Filing  
12/3/2015Clay B. SiegallCEOSell3,720$39.99$148,762.80View SEC Filing  
11/20/2015Felix BakerDirectorBuy329,358$43.94$14,471,990.52View SEC Filing  
11/17/2015Clay B SiegallCEOSell87,473$45.40$3,971,274.20View SEC Filing  
11/11/2015Darren S ClineSVPSell5,769$45.68$263,527.92View SEC Filing  
11/10/2015Felix BakerDirectorBuy934,624$42.95$40,142,100.80View SEC Filing  
11/9/2015Felix BakerDirectorBuy507,300$43.76$22,199,448.00View SEC Filing  
11/6/2015Eric DobmeierCOOSell17,452$42.50$741,710.00View SEC Filing  
11/6/2015Felix BakerDirectorBuy417,924$41.94$17,527,732.56View SEC Filing  
11/5/2015David W GryskaDirectorSell10,000$43.57$435,700.00View SEC Filing  
11/4/2015Clay B. SiegallCEOSell3,718$43.14$160,394.52View SEC Filing  
10/5/2015Clay B. SiegallCEOSell3,718$41.30$153,553.40View SEC Filing  
9/3/2015Clay B. SiegallCEOSell3,718$40.12$149,166.16View SEC Filing  
8/20/2015Clay B. SiegallCEOSell31,754$42.02$1,334,303.08View SEC Filing  
8/20/2015Darren S. ClineSVPSell2,231$42.02$93,746.62View SEC Filing  
8/20/2015Eric DobmeierCOOSell8,548$42.02$359,186.96View SEC Filing  
8/20/2015Jonathan G. DrachmanCMOSell4,462$42.02$187,493.24View SEC Filing  
8/20/2015Todd E. SimpsonCFOSell5,825$42.02$244,766.50View SEC Filing  
8/20/2015Vaughn B. HimesEVPSell5,997$42.02$251,993.94View SEC Filing  
7/6/2015Clay B SiegallCEOSell3,718$46.94$174,522.92View SEC Filing  
6/3/2015Clay B SiegallCEOSell3,718$45.72$169,986.96View SEC Filing  
5/21/2015Felix BakerDirectorBuy950,886$42.49$40,403,146.14View SEC Filing  
5/8/2015Eric DobmeierCOOSell17,074$40.38$689,448.12View SEC Filing  
5/7/2015Felix BakerDirectorBuy1,032,664$35.56$36,721,531.84View SEC Filing  
3/10/2015Felix BakerDirectorBuy285,036$34.66$9,879,347.76View SEC Filing  
3/9/2015Felix BakerDirectorBuy275,717$34.66$9,556,351.22View SEC Filing  
3/4/2015Felix BakerDirectorBuy448,841$34.84$15,637,620.44View SEC Filing  
2/25/2015Felix BakerDirectorBuy281,115$33.92$9,535,420.80View SEC Filing  
1/6/2015Clay B SiegallCEOSell16,804$31.80$534,367.20View SEC Filing  
12/16/2014Felix BakerDirectorBuy2,883,378$31.86$91,864,423.08View SEC Filing  
12/10/2014Felix BakerDirectorBuy1,247,896$33.82$42,203,842.72View SEC Filing  
12/9/2014Felix BakerDirectorBuy128,430$34.16$4,387,168.80View SEC Filing  
12/8/2014Felix BakerDirectorBuy465,316$32.93$15,322,855.88View SEC Filing  
11/12/2014Vaughn B HimesEVPSell10,000$37.52$375,200.00View SEC Filing  
11/10/2014Felix BakerDirectorBuy1,653,925$34.56$57,159,648.00View SEC Filing  
9/4/2014Clay B SiegallCEOSell5,600$42.54$238,224.00View SEC Filing  
8/12/2014Clay B SiegallCEOSell11,200$40.38$452,256.00View SEC Filing  
8/11/2014Clay B SiegallCEOSell2,700$40.05$108,135.00View SEC Filing  
6/13/2014Felix BakerDirectorBuy216,595$39.92$8,646,472.40View SEC Filing  
6/10/2014Clay B SiegallCEOSell11,200$40.14$449,568.00View SEC Filing  
6/9/2014Felix BakerDirectorBuy546,252$38.16$20,844,976.32View SEC Filing  
6/4/2014Felix BakerDirectorBuy281,963$34.86$9,829,230.18View SEC Filing  
5/16/2014Felix BakerDirectorBuy189,611$34.07$6,460,046.77View SEC Filing  
4/3/2014Clay SiegallCEOSell5,600$43.34$242,704.00View SEC Filing  
2/18/2014Clay SiegallCEOSell100,000$51.97$5,197,000.00View SEC Filing  
1/21/2014Eric DobmeierCOOSell56,010$47.92$2,683,999.20View SEC Filing  
1/16/2014Jonathan DrachmanCMOSell1,201$45.75$54,945.75View SEC Filing  
12/16/2013Felix BakerDirectorBuy407,078$39.66$16,144,713.48View SEC Filing  
12/5/2013Felix BakerDirectorBuy1,005,901$43.19$43,444,864.19View SEC Filing  
10/1/2013Clay B SiegallCEOSell2,000$43.87$87,740.00View SEC Filing  
9/10/2013Eric DobmeierCOOSell42,000$46.40$1,948,800.00View SEC Filing  
9/5/2013Eric DobmeierCOOSell75,000$42.64$3,198,000.00View SEC Filing  
9/3/2013Clay B SiegallCEOSell102,000$43.90$4,477,800.00View SEC Filing  
9/3/2013David W GryskaDirectorSell10,000$42.48$424,800.00View SEC Filing  
8/27/2013Todd SimpsonCFOSell37,763$41.45$1,565,276.35View SEC Filing  
8/19/2013Clay SiegallCEOSell7,653$40.91$313,084.23View SEC Filing  
8/19/2013Eric DobmeierCOOSell3,328$40.91$136,148.48View SEC Filing  
8/19/2013Vaughn HimesEVPSell1,736$40.91$71,019.76View SEC Filing  
8/1/2013Clay B SiegallCEOSell2,000$40.03$80,060.00View SEC Filing  
7/12/2013Todd E SimpsonCFOSell92,527$37.45$3,465,136.15View SEC Filing  
7/1/2013Clay B SiegallCEOSell2,000$32.59$65,180.00View SEC Filing  
6/14/2013Srinivas AkkarajuDirectorSell5,000$32.75$163,750.00View SEC Filing  
6/13/2013Vaughn B HimesEVPSell10,000$32.11$321,100.00View SEC Filing  
6/3/2013Clay B SiegallCEOSell2,000$33.88$67,760.00View SEC Filing  
5/10/2013Srinivas AkkarajuDirectorSell17,500$37.17$650,475.00View SEC Filing  
3/6/2013Eric DobmeierCOOSell100,000$29.68$2,968,000.00View SEC Filing  
2/25/2013David W GryskaDirectorSell10,000$27.17$271,700.00View SEC Filing  
2/1/2013Clay B SiegallCEOSell2,000$29.61$59,220.00View SEC Filing  
1/15/2013Thomas C ReynoldsInsiderSell125,079$28.00$3,502,212.00View SEC Filing  
11/1/2012Clay B SiegallCEOSell8,250$25.51$210,457.50View SEC Filing  
9/4/2012Clay B SiegallCEOSell8,250$26.54$218,955.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Seattle Genetics (NASDAQ SGEN) News Headlines

Source:
DateHeadline
Why Seattle Genetics, Inc. Fell Today - Motley FoolWhy Seattle Genetics, Inc. Fell Today - Motley Fool
www.fool.com - December 12 at 3:27 PM
Seattle Genetics (SGEN) Stock Rating Reaffirmed by CowenSeattle Genetics (SGEN) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - December 12 at 1:42 PM
Cantor Fitzgerald Reiterates $50.00 Price Target for Seattle Genetics (SGEN)Cantor Fitzgerald Reiterates $50.00 Price Target for Seattle Genetics (SGEN)
www.americanbankingnews.com - December 12 at 10:04 AM
Seattle Genetics (SGEN) Presents Updated Analyses from Phase 3 ALCANZA ...Seattle Genetics (SGEN) Presents Updated Analyses from Phase 3 ALCANZA ...
www.streetinsider.com - December 12 at 8:55 AM
Seattle Genetics (SGEN) Reports Five-Year Survival Results from Phase 1 Trial of ADCETRIS (Brentuximab Vedotin) in ... - StreetInsider.comSeattle Genetics (SGEN) Reports Five-Year Survival Results from Phase 1 Trial of ADCETRIS (Brentuximab Vedotin) in ... - StreetInsider.com
www.streetinsider.com - December 11 at 3:26 PM
Why Seattle Genetics, Inc. Fell TodayWhy Seattle Genetics, Inc. Fell Today
www.fool.com - December 11 at 2:31 PM
Seattle Genetics (SGEN) Presents Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS ... - StreetInsider.comSeattle Genetics (SGEN) Presents Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS ... - StreetInsider.com
www.streetinsider.com - December 11 at 9:30 AM
Seattle Genetics, Inc. (SGEN) Receives Average Recommendation of "Hold" from BrokeragesSeattle Genetics, Inc. (SGEN) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 11 at 3:38 AM
Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS - Business Wire (press release)Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS - Business Wire (press release)
www.businesswire.com - December 10 at 3:29 PM
Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual MeetingSeattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual Meeting
finance.yahoo.com - December 10 at 3:29 PM
Immunomedics Data Is Good News for Seattle Genetics, Too - Motley FoolImmunomedics' Data Is Good News for Seattle Genetics, Too - Motley Fool
www.fool.com - December 9 at 3:28 PM
Seattle Genetics Highlights Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS - Business Wire (press release)Seattle Genetics Highlights Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS - Business Wire (press release)
www.businesswire.com - December 9 at 3:28 PM
Seattle Genetics (SGEN) Announces Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) - StreetInsider.comSeattle Genetics (SGEN) Announces Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) - StreetInsider.com
www.streetinsider.com - December 9 at 3:28 PM
Seattle Genetics Highlights Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma at ASH Annual MeetingSeattle Genetics Highlights Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma at ASH Annual Meeting
finance.yahoo.com - December 9 at 9:24 AM
Seattle Genetics (SGEN) Stock Rating Upgraded by BidaskClubSeattle Genetics (SGEN) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - December 9 at 7:02 AM
Seattle Genetics (SGEN) Stock Rating Reaffirmed by OppenheimerSeattle Genetics (SGEN) Stock Rating Reaffirmed by Oppenheimer
www.americanbankingnews.com - December 8 at 3:20 PM
Immunomedics Data Is Good News for Seattle Genetics, TooImmunomedics' Data Is Good News for Seattle Genetics, Too
www.fool.com - December 8 at 9:10 AM
Seattle Genetics (SGEN) Announces Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A)Seattle Genetics (SGEN) Announces Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A)
www.streetinsider.com - December 8 at 9:10 AM
Seattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in Patients with Triple Negative Breast Cancer at 2017 San Antonio Breast Cancer SymposiumSeattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in Patients with Triple Negative Breast Cancer at 2017 San Antonio Breast Cancer Symposium
finance.yahoo.com - December 7 at 9:08 AM
Insider Selling: Seattle Genetics, Inc. (SGEN) COO Sells 3,729 Shares of StockInsider Selling: Seattle Genetics, Inc. (SGEN) COO Sells 3,729 Shares of Stock
www.americanbankingnews.com - December 6 at 8:52 PM
Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting - Business Wire (press release)Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting - Business Wire (press release)
www.businesswire.com - December 5 at 8:59 AM
Seattle Genetics, Inc. (SGEN) Insider Sells $599,700.00 in StockSeattle Genetics, Inc. (SGEN) Insider Sells $599,700.00 in Stock
www.americanbankingnews.com - December 4 at 8:40 PM
Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual MeetingSeattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting
finance.yahoo.com - December 4 at 9:08 AM
Market-Moving News Is on Tap for Seattle GeneticsMarket-Moving News Is on Tap for Seattle Genetics
finance.yahoo.com - December 4 at 9:08 AM
What Analysts Recommend for United Therapeutics in November 2017What Analysts Recommend for United Therapeutics in November 2017
finance.yahoo.com - December 4 at 9:08 AM
Why Is Seattle Genetics (SGEN) Down 4.1% Since the Last Earnings Report? - NasdaqWhy Is Seattle Genetics (SGEN) Down 4.1% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - December 1 at 11:46 AM
$109.73 Million in Sales Expected for Seattle Genetics, Inc. (SGEN) This Quarter$109.73 Million in Sales Expected for Seattle Genetics, Inc. (SGEN) This Quarter
www.americanbankingnews.com - November 29 at 1:26 PM
Why Is Seattle Genetics (SGEN) Down 4.1% Since the Last Earnings Report?Why Is Seattle Genetics (SGEN) Down 4.1% Since the Last Earnings Report?
finance.yahoo.com - November 29 at 9:09 AM
Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : November 28, 2017Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : November 28, 2017
finance.yahoo.com - November 28 at 8:21 AM
Zacks: Analysts Expect Seattle Genetics, Inc. (SGEN) Will Post Earnings of -$0.44 Per ShareZacks: Analysts Expect Seattle Genetics, Inc. (SGEN) Will Post Earnings of -$0.44 Per Share
www.americanbankingnews.com - November 27 at 3:18 AM
Seattle Genetics, Inc. (SGEN) Price Target Raised to $69.00Seattle Genetics, Inc. (SGEN) Price Target Raised to $69.00
www.americanbankingnews.com - November 27 at 12:34 AM
Seattle Genetics, Inc. – Value Analysis (NASDAQ:SGEN) : November 15, 2017Seattle Genetics, Inc. – Value Analysis (NASDAQ:SGEN) : November 15, 2017
finance.yahoo.com - November 18 at 11:53 AM
Seattle Genetics, Inc. (SGEN) Raised to "C" at TheStreetSeattle Genetics, Inc. (SGEN) Raised to "C" at TheStreet
www.americanbankingnews.com - November 18 at 7:40 AM
Seattle Genetics, Inc. (SGEN) Director Marc E. Lippman Sells 3,000 SharesSeattle Genetics, Inc. (SGEN) Director Marc E. Lippman Sells 3,000 Shares
www.americanbankingnews.com - November 17 at 10:49 PM
Eric Dobmeier Sells 9,600 Shares of Seattle Genetics, Inc. (SGEN) StockEric Dobmeier Sells 9,600 Shares of Seattle Genetics, Inc. (SGEN) Stock
www.americanbankingnews.com - November 17 at 10:26 PM
Seattle Genetics, Inc. (SGEN) COO Sells $2,038,750.00 in StockSeattle Genetics, Inc. (SGEN) COO Sells $2,038,750.00 in Stock
www.americanbankingnews.com - November 17 at 10:26 PM
Seattle Genetics, Inc. (SGEN) Given Consensus Rating of "Hold" by BrokeragesSeattle Genetics, Inc. (SGEN) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 16 at 6:02 AM
Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : November 14, 2017Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : November 14, 2017
finance.yahoo.com - November 15 at 8:24 AM
Seattle Genetics, Inc. (SGEN) Insider Clay B. Siegall Sells 18,832 SharesSeattle Genetics, Inc. (SGEN) Insider Clay B. Siegall Sells 18,832 Shares
www.americanbankingnews.com - November 14 at 11:02 PM
Seattle Genetics Adcetris Gets FDA Nod for Label ExpansionSeattle Genetics' Adcetris Gets FDA Nod for Label Expansion
www.nasdaq.com - November 14 at 7:49 AM
Seattle Genetics' Adcetris Gets FDA Nod for Label ExpansionSeattle Genetics' Adcetris Gets FDA Nod for Label Expansion
finance.yahoo.com - November 14 at 7:49 AM
Seattle Genetics (SGEN) Announces FDA Approval of ADCETRISSeattle Genetics (SGEN) Announces FDA Approval of ADCETRIS
www.streetinsider.com - November 10 at 12:06 PM
Report: Exploring Fundamental Drivers Behind Tronox, Ameren, GrubHub, Patterson Companies, AVEO Pharmaceuticals, and Seattle Genetics – New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Tronox, Ameren, GrubHub, Patterson Companies, AVEO Pharmaceuticals, and Seattle Genetics – New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - November 10 at 12:06 PM
Seattle Genetics, Inc. (SGEN) Expected to Post Quarterly Sales of $109.73 MillionSeattle Genetics, Inc. (SGEN) Expected to Post Quarterly Sales of $109.73 Million
www.americanbankingnews.com - November 10 at 5:44 AM
Seattle Genetics (SGEN) Announces FDA Approval of ADCETRIS - StreetInsider.comSeattle Genetics (SGEN) Announces FDA Approval of ADCETRIS - StreetInsider.com
www.streetinsider.com - November 9 at 6:19 PM
Seattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic ...Seattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic ...
www.businesswire.com - November 9 at 1:16 PM
Seattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial CancerSeattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - November 9 at 1:16 PM
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)
finance.yahoo.com - November 9 at 1:15 PM
Seattle Genetics, Inc. (SGEN) Coverage Initiated at CannSeattle Genetics, Inc. (SGEN) Coverage Initiated at Cann
www.americanbankingnews.com - November 8 at 3:40 PM
Q4 2017 Earnings Estimate for Seattle Genetics, Inc. (SGEN) Issued By Oppenheimer HoldingsQ4 2017 Earnings Estimate for Seattle Genetics, Inc. (SGEN) Issued By Oppenheimer Holdings
www.americanbankingnews.com - November 6 at 8:24 AM

SEC Filings

Seattle Genetics (NASDAQ:SGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Seattle Genetics (NASDAQ:SGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Seattle Genetics (NASDAQ SGEN) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.